AU2017340314B2 - Cysteine modified antibody-drug conjugate and preparation method thereof - Google Patents

Cysteine modified antibody-drug conjugate and preparation method thereof Download PDF

Info

Publication number
AU2017340314B2
AU2017340314B2 AU2017340314A AU2017340314A AU2017340314B2 AU 2017340314 B2 AU2017340314 B2 AU 2017340314B2 AU 2017340314 A AU2017340314 A AU 2017340314A AU 2017340314 A AU2017340314 A AU 2017340314A AU 2017340314 B2 AU2017340314 B2 AU 2017340314B2
Authority
AU
Australia
Prior art keywords
antibody
pab
cysteine
mmae
tdc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017340314A
Other languages
English (en)
Other versions
AU2017340314A1 (en
Inventor
Lan Chen
Jie Li
Weili WAN
Yixi Wang
Yongguo YU
Yi Zhu
Shi ZHUO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Systimmune Inc
Original Assignee
Systimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune Inc filed Critical Systimmune Inc
Publication of AU2017340314A1 publication Critical patent/AU2017340314A1/en
Application granted granted Critical
Publication of AU2017340314B2 publication Critical patent/AU2017340314B2/en
Assigned to Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. reassignment Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Request for Assignment Assignors: SICHUAN BAILI PHARM CO., LTD.
Assigned to SYSTIMMUNE, INC. reassignment SYSTIMMUNE, INC. Request for Assignment Assignors: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2017340314A 2016-10-08 2017-09-30 Cysteine modified antibody-drug conjugate and preparation method thereof Active AU2017340314B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610876568.9 2016-10-08
CN201610876568 2016-10-08
PCT/CN2017/104706 WO2018064964A1 (zh) 2016-10-08 2017-09-30 半胱氨酸改造的抗体-毒素偶联物及其制备方法

Publications (2)

Publication Number Publication Date
AU2017340314A1 AU2017340314A1 (en) 2019-05-02
AU2017340314B2 true AU2017340314B2 (en) 2021-04-29

Family

ID=61533952

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017340314A Active AU2017340314B2 (en) 2016-10-08 2017-09-30 Cysteine modified antibody-drug conjugate and preparation method thereof

Country Status (12)

Country Link
US (1) US11484605B2 (https=)
EP (1) EP3524273B1 (https=)
JP (1) JP6998386B2 (https=)
KR (2) KR102480873B1 (https=)
CN (3) CN117398475A (https=)
AU (1) AU2017340314B2 (https=)
CA (1) CA3039559A1 (https=)
ES (1) ES3040239T3 (https=)
IL (1) IL265838B2 (https=)
RU (1) RU2762594C2 (https=)
SG (1) SG11201903084UA (https=)
WO (1) WO2018064964A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018288030B2 (en) * 2017-06-20 2022-02-03 Systimmune, Inc. Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (TDC)
CN110872339A (zh) * 2018-08-30 2020-03-10 中国人民解放军军事科学院军事医学研究院 含有芳硝基的连接子、含连接子的抗体偶联药物及连接子的用途
CA3085001C (en) * 2019-05-20 2021-10-05 Mabplex International, Ltd. One-pot process for preparing intermediate of antibody-drug conjugate
KR102720758B1 (ko) * 2021-06-25 2024-10-22 강원대학교산학협력단 주류담배연기 노출 장치
TW202417057A (zh) * 2022-10-26 2024-05-01 大陸商同潤生物醫藥(上海)有限公司 人源化的l1cam抗體藥物偶聯物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101065151A (zh) * 2004-09-23 2007-10-31 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
CN102770456A (zh) * 2009-12-04 2012-11-07 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
WO2015157595A1 (en) * 2014-04-11 2015-10-15 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies
WO2016131769A2 (en) * 2015-02-16 2016-08-25 Lonza Ltd Antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001334A1 (es) * 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
EP2176295B1 (en) * 2007-07-16 2014-11-19 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
NZ584514A (en) * 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
KR101607346B1 (ko) * 2008-01-31 2016-03-29 제넨테크, 인크. 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
EP2953976B1 (en) * 2013-02-08 2021-03-24 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
CN106467575B (zh) 2015-08-18 2020-07-31 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物
TWI812873B (zh) 2015-11-30 2023-08-21 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段
CN106866822A (zh) 2016-12-25 2017-06-20 四川百利药业有限责任公司 半胱氨酸改造的抗体‑毒素偶联物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101065151A (zh) * 2004-09-23 2007-10-31 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
CN102770456A (zh) * 2009-12-04 2012-11-07 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
WO2015157595A1 (en) * 2014-04-11 2015-10-15 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies
WO2016131769A2 (en) * 2015-02-16 2016-08-25 Lonza Ltd Antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VOYNOV, V. et al., "Design and Application of Antibody Cysteine Variants", Bioconjugate Chem., (2010-01-21), vol. 21, no. 2, pages 385 - 392 *

Also Published As

Publication number Publication date
SG11201903084UA (en) 2019-05-30
EP3524273A4 (en) 2020-07-15
US11484605B2 (en) 2022-11-01
CN107789630A (zh) 2018-03-13
IL265838B2 (en) 2024-03-01
EP3524273B1 (en) 2025-06-18
RU2019113758A3 (https=) 2020-12-25
KR102579211B1 (ko) 2023-09-15
IL265838B1 (en) 2023-11-01
JP6998386B2 (ja) 2022-02-10
CN117398475A (zh) 2024-01-16
CN118846112A (zh) 2024-10-29
EP3524273A1 (en) 2019-08-14
KR20190065374A (ko) 2019-06-11
US20200129635A1 (en) 2020-04-30
JP2019533017A (ja) 2019-11-14
WO2018064964A1 (zh) 2018-04-12
KR20230003663A (ko) 2023-01-06
AU2017340314A1 (en) 2019-05-02
KR102480873B1 (ko) 2022-12-26
RU2762594C2 (ru) 2021-12-21
RU2019113758A (ru) 2020-11-09
NZ752462A (en) 2024-10-25
ES3040239T3 (en) 2025-10-29
IL265838A (en) 2019-06-30
CA3039559A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
CN108853514B (zh) 具有两种不同药物的抗体药物偶联物
JP7224365B2 (ja) 酸性自己安定化ジョイントを有する抗体薬物複合体
AU2017340314B2 (en) Cysteine modified antibody-drug conjugate and preparation method thereof
AU646121B2 (en) Acid-labile linker molecules
JP2024503074A (ja) カンプトテシン抗体－薬物コンジュゲート及びその使用方法
CN106467575A (zh) 半胱氨酸改造的抗体-毒素偶联物
KR20250150111A (ko) 캄프토테신 유도체 및 이의 접합체, 이의 제조 방법 및 의학적 용도
CN106866822A (zh) 半胱氨酸改造的抗体‑毒素偶联物
JP7549631B2 (ja) システイン改変抗体－毒素複合体（ｔｄｃ）の部位特異的結合サイトのスクリーニング
WO2025031923A1 (en) Imidazo[4,5-d]pyridazine compounds and conjugates thereof, their preparation, and their therapeutic applications
CN119053607A (zh) 喜树碱类化合物及其偶联物、其制备方法和用途
CN116966314A (zh) 一种包含亲水性糖结构的配体-药物偶联物
IL313262A (en) Anti-human trop2 antibody-camptothecin drug conjugate and medical use thereof
HK40005253A (en) Cysteine modified antibody-drug conjugate and preparation method thereof
TWI903241B (zh) 一種帶有高穩定性親水連接單元的奧瑞他汀類藥物及其偶聯物
HK40005253B (en) Cysteine modified antibody-drug conjugate and preparation method thereof
TWI884535B (zh) 抗cd33抗體和抗cd33抗體-藥物偶聯物及其用途
TW202546005A (zh) 抗體-奧瑞他汀藥物偶聯物以及其製造及使用方法
HK40035179A (en) Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (tdc)
TW202546010A (zh) 抗體-奧瑞他汀藥物偶聯物及其醫藥用途
WO2026030396A1 (en) Anti-human ror1 antibody-drug conjugate and uses thereof
CN119792570A (zh) 一种靶向cldn18.2的抗体偶联药物及其制备方法和应用
TW202515913A (zh) Nectin-4抗體及抗體藥物結合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER(S): SICHUAN BAILI PHARM CO., LTD.

PC Assignment registered

Owner name: SYSTIMMUNE, INC.

Free format text: FORMER OWNER(S): BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.